The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Day One Biopharmaceuticals Inc shares valued at $160,055 were sold by Blackman Samuel C. on Mar 25 ’24. At $16.01 per share, Blackman Samuel C. sold 10,000 shares. The insider’s holdings dropped to 1,184,662 shares worth approximately $17.07 million following the completion of this transaction.
Also, Blackman Samuel C. sold 30,000 shares, netting a total of over 457,314 in proceeds. Following the sale of shares at $15.24 each, the insider now holds 1,194,662 shares.
Before that, Blackman Samuel C. had sold 20,000 shares from its account. In a trade valued at $322,166, the HEAD OF R&D traded Day One Biopharmaceuticals Inc shares for $16.11 each. Upon closing the transaction, the insider’s holdings decreased to 20,000 shares, worth approximately $17.65 million.
As published in a research note from BofA Securities on April 25, 2023, Day One Biopharmaceuticals Inc [DAWN] has been rated down from a Buy to an Underperform and the price target has been revised to $9 from $34. Analysts at CapitalOne started covering the stock with ‘”an Overweight”‘ outlook in a report released in early February. As of February 03, 2023, Oppenheimer has initiated its “Perform” rating for DAWN. Earlier on December 15, 2022, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for DAWN stock.
Analyzing DAWN Stock Performance
During the last five days, there has been a drop of approximately -7.63%. Over the course of the year, Day One Biopharmaceuticals Inc shares have dropped approximately -1.30%. Shares of the company reached a 52-week high of $17.85 on 03/01/24 and a 52-week low of $13.42 on 01/19/24. A 50-day SMA is recorded $15.29, while a 200-day SMA reached $13.39. Nevertheless, trading volume fell to 0.6 million shares from 0.54 million shares the previous day.
Support And Resistance Levels for Day One Biopharmaceuticals Inc (DAWN)
According to the 24-hour chart, there is a support level at 13.91, which, if violated, would cause prices to drop to 13.42. In the upper region, resistance lies at 14.75. The next price resistance is at 15.10. RSI (Relative Strength Index) is 44.60 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.93, which suggests the price will decrease in the coming days. Percent R is at 79.20%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is Day One Biopharmaceuticals Inc subject to short interest?
Stocks of Day One Biopharmaceuticals Inc saw a sharp steep in short interest on Mar 15, 2024 dropping by -0.11 million shares to 9.61 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 9.72 million shares. A decline of -1.14% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 13.25 of the overall float, the days-to-cover ratio (short ratio) decline to 13.25.
